Your session is about to expire
← Back to Search
124I-cG250 Imaging for Kidney Cancer Response Detection
N/A
Waitlist Available
Led By Steven Larson, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects must be planned for treatment with approved treatment doses of a VEGF receptor TKI (e.g., sunitinib, pazopanib, cabozantinib, axitinib, sorafenib, lenvatinib)
ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial will test whether 124I-cG250 PET/CT can show if sunitinib or pazopanib is working against kidney cancer sooner than a regular CT scan.
Who is the study for?
Adults with advanced/metastatic clear cell renal carcinoma, who are about to start VEGF receptor TKI therapy like sunitinib or pazopanib. They should be in good enough health for the trial (ECOG ≤2), have manageable side effects from previous treatments, and meet specific blood test criteria. Pregnant women, those with certain medical conditions or a history of severe reactions to similar drugs can't participate.Check my eligibility
What is being tested?
The study is testing if a new PET/CT scan using the radioactive tracer 124I-cG250 can detect early responses to kidney cancer treatment better than regular CT scans. This involves an antibody that targets cancer cells and shows up on scans, potentially identifying treatment effectiveness sooner.See study design
What are the potential side effects?
Possible side effects may include allergic reactions due to the antibody used or exposure to radiation from the tracer Iodine-124. There could also be risks associated with contrast agents used during CT scans such as kidney damage or allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for treatment with specific cancer drugs targeting blood vessel growth.
Select...
I can do most of my daily activities on my own.
Select...
My cancer is advanced or has spread, and it's confirmed to be clear cell carcinoma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
accuracy of predicting
Secondary outcome measures
Detection of metastatic lesions
To evaluate the radiation dosimetry of 124I-cG250.
progression-free survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: 124IcG250Experimental Treatment1 Intervention
This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
Find a Location
Who is running the clinical trial?
Telix PharmaceuticalUNKNOWN
1 Previous Clinical Trials
12 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,603 Total Patients Enrolled
Steven Larson, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
37 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You cannot have a CT scan with a special dye.You have been treated with medications containing certain types of proteins in the past.I am scheduled for treatment with specific cancer drugs targeting blood vessel growth.I can do most of my daily activities on my own.My side effects from previous cancer treatments are mild or gone.I am not pregnant or breast-feeding.My thyroid condition is not under control.I haven't had a stroke, mini-stroke, or uncontrolled seizures in the last year.I do not have active hepatitis B/C or HIV.I am 18 years old or older.I cannot take IOSATTM due to health reasons listed on its package.I have not taken any VEGF receptor inhibitors recently.I have not had a heart attack or unstable heart conditions in the last 6 months.Your disease can be measured using specific imaging techniques.Your blood test results must meet certain limits within 2 weeks before the study starts. This includes white blood cell count, bilirubin level, platelet count, and liver enzyme levels.My cancer is advanced or has spread, and it's confirmed to be clear cell carcinoma.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are researchers recruiting volunteers for this experiment?
"As indicated on clinicaltrials.gov, the recruitment phase for this medical experiment has concluded; it was first posted in April 2012 and was last updated in May of 2022. Nevertheless, there are still over two-thousand six hundred other trials offering participation opportunities at present."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger